menu
    • menu

    Company profile for ViGeneron

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ViGeneron is based on our passion to deliver gene therapy innovations and advances to people in need. Our proprietary science solves major limitations in current gene therapy approaches. At ViGeneron we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is b...
    ViGeneron is based on our passion to deliver gene therapy innovations and advances to people in need. Our proprietary science solves major limitations in current gene therapy approaches. At ViGeneron we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two unique and proprietary adeno-associated virus (AAV) technology platforms. ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ViGeneronGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Semmelweisstr,3, Planegg, 82152, DE
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vigeneron.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    VeonGen Unveils VG801 Progress in Stargardt Disease at ARVO 2026
    VeonGen Unveils VG801 Progress in Stargardt Disease at ARVO 2026

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262229/0/en/VeonGen-Announces-Clinical-Progress-of-VG801-Gene-Therapy-in-Stargardt-Disease-with-an-Oral-Presentation-at-ARVO-2026.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    VeonGen's VG801 Therapy for Stargardt Gets FDA RMAT Designation
    VeonGen's VG801 Therapy for Stargardt Gets FDA RMAT Designation

    21 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/21/3137061/0/en/VeonGen-Therapeutics-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-VG801-Gene-Therapy-for-Stargardt-Disease.html

    GLOBENEWSWIRE
    21 Aug 2025
    Share Share
    ViGeneron Rebrands, Gains FDA RPDD for VG801 in Stargardt
    ViGeneron Rebrands, Gains FDA RPDD for VG801 in Stargardt

    05 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/05/3094322/0/en/ViGeneron-Rebrands-as-VeonGen-Therapeutics-and-Announces-FDA-Rare-Pediatric-Disease-Designation-and-Clinical-Progress-for-Lead-Gene-Therapy-VG801-in-Stargardt-Disease.html

    GLOBENEWSWIRE
    05 Jun 2025
    Share Share
    ViGeneron Gets Rare Pediatric Designation For VG901 Retinitis Trial
    ViGeneron Gets Rare Pediatric Designation For VG901 Retinitis Trial

    08 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/08/3006207/0/en/ViGeneron-Announces-FDA-Rare-Pediatric-Disease-Designation-for-VG901-and-DSMB-Approval-to-Advance-Dose-Escalation-in-Phase-1b-Retinitis-Pigmentosa-Trial.html

    GLOBENEWSWIRE
    08 Jan 2025
    Share Share
    ViGeneron Announces FDA Clearance for VG801 mRNA Gene Therapy
    ViGeneron Announces FDA Clearance for VG801 mRNA Gene Therapy

    18 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/18/2999005/0/en/ViGeneron-Announces-FDA-Clearance-of-IND-for-Novel-mRNA-Trans-Splicing-Gene-Therapy-VG801-to-Treat-Stargardt-Disease-and-Other-ABCA4-Linked-Retinal-Dystrophies.html

    GLOBENEWSWIRE
    18 Dec 2024
    Share Share
    ViGeneron Doses First Patient in VG901 Phase 1b Trial
    ViGeneron Doses First Patient in VG901 Phase 1b Trial

    10 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/10/2860550/0/en/ViGeneron-Announces-First-Patient-Dosed-in-Phase-1b-Clinical-Trial-of-VG901-for-the-Intravitreal-Treatment-of-Retinitis-Pigmentosa.html

    GLOBENEWSWIRE
    10 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search